cyrilzakka/clinical-trials huggingface dataset:
Standard Oxygen Versus High Flow Nasal Cannula Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure

First-line therapy of patients with acute respiratory failure consists in oxygen delivery through standard oxygen, high-flow nasal oxygen therapy through cannula or non-invasive ventilation. Non-invasive ventilation in acute hypoxemic respiratory failure is not recommended. In a large randomized controlled study, high-flow nasal oxygen has been described as superior to non-invasive ventilation and standard oxygen in terms of mortality but not of intubation. Paradoxically in immunocompromised patients, high-flow nasal oxygen has not been shown to be superior to standard oxygen. To improve the level of evidence of daily clinical practice, we propose comparing high-flow nasal oxygen versus standard oxygen, in terms of mortality in all patients with acute hypoxemic respiratory failure


Eligibility Criteria:
Inclusion Criteria:

All consecutive patients older than 18 years with an acute hypoxemic respiratory failure will be enrolled if they meet all the following criteria:

* Respiratory rate \>25 breaths/min whatever the oxygen support
* Pulmonary infiltrate,
* PaO2/FiO2 ≤200 mmHg
* Informed consent from the patient or relatives.

Exclusion Criteria:

* PaCO2 \> 45 mm Hg
* Need for emergent intubation: pulse oximetry \< 90% with maximum oxygen support, respiratory arrest, cardiac arrest, or Glasgow coma scale below 8 points
* Hemodynamic instability defined by signs of hypoperfusion or use of vasopressors \> 0.3 µg/kg/min
* Glasgow coma scale equal to or below 12 points
* Exacerbation of chronic lung disease including chronic obstructive pulmonary disease (grade 3 or 4 of Gold classification), or another chronic lung disease with long term oxygen or ventilatory support
* Cardiogenic pulmonary edema as main reason for acute respiratory failure
* Coronavirus SARS-2 infection as reason for acute respiratory failure (the SOHO-COVID study has been completed)
* Post-extubation respiratory failure within 7 days after extubation,
* Post-operative patients within 7 days after abdominal or cardiothoracic surgery,
* Do not intubate order;
* Already included in the study, refusal to participate or participation in another interventional study with the same primary outcome.
* Patients without any healthcare insurance scheme or not benefiting from it through a third party,
* Persons under law protection, namely minors, pregnant or breastfeeding women, persons deprived of their liberty by a judicial or administrative decision.
Relationship Between Oral Lichen Planus and Autoimmune Thyroid Diseases

On the basis of previous studies, a validation cohort will be established to explore the relationship between oral lichen planus and autoimmune thyroid diseases, and a disease efficacy prediction strategy can be formed.

For oral lichen planus patients, the prevalence of Hashimoto's thyroiditis will be investigated and the relationship between levels of anti-TG, anti-TPO antibodies and severity of oral lichen planus will be determined.

Besides, for patients with Hashimoto's thyroiditis, the prevalence of oral lichen planus will be investigated and the relationship between levels of anti-TG, anti-TPO antibodies and severity of oral lichen planus will be determined.

Eligibility Criteria:
Inclusion Criteria:

* OLP patients without systemic disease

Exclusion Criteria:

* OLP patients with severe periodontal disease
New Measures for Tracheobronchial Anatomy

The right-sided double lumen endobronchial tube (R-DLT) is seldom. The principal cause of reticence for using the R-DLT are the difficult positioning of its lateral orifice in front of the origin of the right upper lobe (RUL) and the variability of the length of the right main stem bronchus (RMSB). Both the angle between the right upper lobe (RUL) bronchus origin and the RMSB and the length of the RMSB can be measured with high resolution CT-scan. These measures can be useful in clinical practice as they help to determine when a R-DLT should not be used or used with caution when facing a large variation of the angle of the RUL or a proximal implantation of a RUL bronchus .

Since the introduction in the early '80s of the disposable double-lumen endobronchial tube (DLT), combined with the use of fiberoptic bronchoscopy (FOB) to confirm its positioning, some controversies have aroused; the main concern being the use of the right-sided double-lumen endobronchial tube (R-DLT). Alongside this persistent controversy, the anatomy of the right tracheo-bronchial tree seems to be the principal cause of reticence for using the R-DLT. Compared to the left main stem bronchus, this anatomy is relatively complex and can be divided in two issues: 1) the variable length of the right main-stem bronchus (RMSB) and consequently, the variable level of insertion of the right upper lobe (RUL) bronchus on the lateral part of the RMSB and 2) the alignment of the lateral orifice of the R-DLT in regard of the RUL bronchus origin. A as part of an extensive study of the tracheo-bronchial tree anatomy with high resolution CT-scan, we had the opportunity to measure differently the length of the main stem right bronchus and the angulation between the RUL bronchus origin and the lateral aspect of the right side main stem bronchus.

Eligibility Criteria:
Inclusion Criteria:

* Aged 35 to 85 years old

Exclusion Criteria:

* Unavailable weight and height
* Tracheobronchial tree pathologies (e.g. : tracheomalacia, tracheobronchomegaly, endobronchial lesions, bronchiectasis, etc.)
* Mediastinal pathologies inducing an extrinsic compression of the tracheobronchial tree.
* Pulmonary pathologies inducing a deformation of the tracheobronchial tree (e.g.: retraction, important atelectasis, pulmonary fibrosis, chronic tuberculosis, etc.)
* Patients that have had a treatment or surgery inducing a deformation of the tracheobronchial tree (e.g.: lobectomy, pneumonectomy, radiotherapy)
* An important musculoskeletal deformity at the thoracic level
* Low-quality CT scan exams (e.g.: significant kinetic artifacts where measurements should be taken
Topical Application of Tranexamic Acid Reduces Postoperative Blood Loss in Total Hip Arthroplasty

Tranexamic acid has been shown to reduce postoperative blood losses and transfusion requirements in a number of types of surgery. Most trials in orthopedic surgery have been conducted intravenously in arthroplasty, hip fracture and spine surgeries. This study would aim to see the effect of topical use of tranexamic acid in reduction of blood loss and transfusions for total hip arthroplasty


Eligibility Criteria:
Inclusion Criteria:

* Patient who are to undergo elective total hip arthroplasty.
* Must be primary arthroplasty.
* Must be single-side arthroplasty.
* Must be older than 18 years.

Exclusion Criteria:

* Cemented arthroplasty.
* Patients with a platelet count less than 100, 000/mm3 or history of thrombocytopenia .
* Patients with known coagulopathy (APTT or PT outside normal range pre-operatively).
* Patients who have a past medical history of thrombi-embolism at any time.
* Patients with anemia (hemoglobin levels less than 8 mg/dl or hematocrit \<24%).
* Patients with documented DVT or PE at screening or in past three months.
* Patients having known hypersensitivity to tranexamic acid or any other. constituent of the product.
* Patients with any associated major illness (e.g., severe cardiac \[New York Heart Association Class III or IV\] or respiratory disease).
* Anticoagulants (other than LMWH or heparin in prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or completed within last week.
* Jehovah's Witnesses, or any other group of patients with ethical objections to receiving blood products.
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for unresectable biliary tract cancer.

Gemcitabine/cisplatin combination therapy (GC) has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). Investigators have evaluated the efficacy and safety of gemcitabine/cisplatin/S-1 combination therapy (GCS) for patients with advanced BTC and observed the promising efficacy. In this randomized phase Ⅲ study, investigators aimed to compare GCS with GC in patients with advanced BTC.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with cytologically or histologically proved biliary tract cancer
2. age \>=20 years
3. Performance Status (PS) 0-2
4. No prior history of chemotherapy or radiotherapy.
5. Adequate bone marrow function (neutrophil count \>=1,500/mm3, and platelet count \>=100,000/mm3), liver function (total bilirubin \>=3 mg/dL and AST/ALT \>=150 IU/L), and renal function (creatinine clearance \>=45 mL/min)
6. Adequate oral intake
7. Provided written informed consent -

Exclusion Criteria:

1. Patients with interstitial pneumonia or pulmonary fibrosis
2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months
3. Patients with severe active infection
4. Patients with moderate or marked pleural effusion or ascites necessitating drainage
5. Patients with a history of severe drug allergy
6. Patients with other serious comorbid disease
7. Patients who are pregnant or lactating, or have an intention to get pregnant
8. Patients with mental disease
9. Patients who are judged inappropriate for the entry into the study by the principle doctor

   -
Macrolane Retrospective Study

This is a retrospective, multicenter chart review of medical records on the use of Macrolane for female breast enhancement.

The primary objective is to evaluate the safety profile of Macrolane Volume Restoration Factor 20 and Macrolane Volume Restoration Factor 30 when used for female breast enhancement in clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Females treated with Macrolane Volume Restoration Factor 20 and/or Volume Restoration Factor 30 for breast enhancement.
* Signed Informed Consent

Exclusion Criteria:

* Subjects that have actively asked not to be contacted by the clinic
* Subjects that have participated or participates in clinical studies with Macrolane for breast enhancement
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). Subjects with previously untreated, resectable SCCHN, will be recruited onto this trial and will initially undergo pre-treatment diagnostic imaging and biological sample collection. These subjects will undergo pre-operative study treatment for a 3 to 4-week period prior to a scheduled surgical resection.


Eligibility Criteria:
Inclusion Criteria:

* Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
* Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
* Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN of the oral cavity, pharynx, or larynx
* Macroscopic complete resection of the primary tumor must be planned and subjects should have no medical contraindication to surgery.
* Subject consents to and has tumor accessible for tumor biopsy pre-treatment.
* Subjects must have acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests.

Exclusion Criteria:

* Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
* Subject has unresectable or inoperable tumors
* Subject has primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary tumors
* Subject has evidence of distant metastasis
* Subject is a pregnant or nursing female.
* Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
* Subject has active autoimmune disease.
* Subject has clinically significant ophthalmologic disease.
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Eligible male subjects will be randomized to receive either MCS-2 or placebo for 12 weeks. Subjects are those not currently on any medicines for BPH or LUTS. During and at the end of the 12-week treatment period, randomized subjects will be evaluated for efficacy and safety parameters. All subjects will be advised to maintain a normal diet, similar to what was consumed before joining the study.

Eligibility Criteria:
Inclusion Criteria:

* Age ≧ 40 years old.
* Not being treated for BPH or LUTS.
* PSA ≦ 4 ng/ml and no pathologically-proven prostate cancer.
* I-PSS ≥ 10
* No known malignancy
* AST/ALT ≦ 3X UNL.
* Creatinine ≦ 3X UNL.
* Subjects who sign the informed consent form.

Exclusion Criteria:

* Subjects' LUTS are not BPH-related
* Have been treated with pelvis irradiation or pelvic surgery.
* Plan to undergo any invasive procedures within the study period.
* Active infection or inflammation.
* Considered ineligible by the investigators.
Evaluating the Safety and Efficacy of Telemedicine Neurology Assessments on a Mobile Stroke Unit

The goal of this clinical trial is to compare a telemedicine neurologist staffing model to a traditional on-board model in patients being assessed for suspected acute stroke on a mobile stroke unit.

This study is a prospective randomized mobile stroke unit trial comparing two staffing models: 1) a neurologist reviewing the patient via telemedicine (intervention) versus 2) an onboard neurologist assessing the patient in-person (comparator). Daily periods of remote (telemedicine) or in person (onboard) neurologist assessments will be randomly determined using an adaptive design.

Eligibility Criteria:
Inclusion Criteria:

1. Adults \>=18 years of age
2. Presenting within 24 hours of symptom onset or last known well.
3. Patients assessed by MSU without cancellation (either by the local ambulance team or by MSU) prior to attending the patient.

Exclusion Criteria:

1. Attendance of the Melbourne MSU is deemed unnecessary by either the local paramedic team or the MSU team based on provided information prior to arrival on scene.
2. The patient presents significant medical or logistical challenges which greatly delay standard treatment.
3. Any other medical contraindication at the discretion of the investigator.
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.

This is a multicenter, prospective, open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days

Eligibility Criteria:
Inclusion Criteria:

* Central or inferior corneal fluorescein staining defined by the Oxford Scale
* Reduced tear break up time (TBUT) ≤ 10 seconds.
* Able to comprehend and sign a statement of informed consent.
* Willing and able to complete all required postoperative visits.

Exclusion Criteria:

* Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure performed in the study eye within the last 3 months or at any time that in the investigator's clinical judgment if it would interfere with the outcome measures of this study.
* Clinically significant ocular trauma.
* Active ocular Herpes simplex or Herpes Zoster infection
* Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) that is active, at the discretion of the investigator.
* Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye), at the discretion of the investigator.
* Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the questions in the survey and examination findings, in the opinion of the investigator.
* Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis that would interfere with study findings, in the opinion of the investigator.
* Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
* Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that would interfere with study findings, in the opinion of the investigator.
* Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
* Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.
Comparison of Anterior Chest Compression Assist and Abdominal Thrust Assist Technique COPD

A total 34 patients will be taken. 2 groups will be created to apply intervention. After signing consent form, 17 patients in group A will be given abdominal thrust assist technique and 17 patients in group B will be given anterior chest compression technique.

Patient is instructed to take in a deep breath and hold it. Then, just as the patient is instructed to cough, the therapist applies a quick push up and in under the diaphragm with the heel of the hand. In Anterior chest compression: the therapist places one arm across the patient's pectorals and the other parallel to it. After the patient takes a maximal breath, the therapist pushes down to help the patient cough. The greatest force is applied through the lower chest during expulsion. A total 34 patients will be taken. 2 groups will be created to apply intervention. After signing consent form, 17 patients in group A will be given abdominal thrust assist technique and 17 patients in group B will be given anterior chest compression technique. Baseline treatment given to both groups will include percussion and tapping. The data collected will then be analyzed using IBM SPSS version 25.

Eligibility Criteria:
Inclusion Criteria:

* uncontrolled Tachycardia
* Unconscious patients
* In neuro-compromised patients with Cognitive dysfunction
* Recent esophageal surgery
* Acute abdominal distension -Recent Broncho-pleural fistula - Pulmonary embolism, pneumothorax hemothorax
* Unstable head and neck fracture

Exclusion Criteria:

* Breathlessness, Cough and sputum scale (BCSS)
* Modified Borg Dyspnea scale
* Peak Flow Meter
* Pulse Oximeter
Study in Subjects With Small Primary Choroidal Melanoma

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma.

Throughout the study, subjects will be monitored through medical and ophthalmic assessments. Subjects will be followed for a total of 2 years.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of choroidal melanoma

Exclusion Criteria:

* Have known contraindications or sensitivities to the study drug
IVIM & OLINK in Sarcoma

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Tumour hypoxia has been implicated as a major driver in STS metastatic dissemination. Despite this, patients are not routinely assessed for hypoxia, largely due to the cost and difficulty involved. PET hypoxia imaging using Fluorine-18-labelled nitroimidazole-based agents such as fluoroazomycin arabinoside (FAZA) provide non-invasive in vivo quantification of hypoxia \[5\], including in STS. The expense and unproven clinical value of these agents and the long times between their injection and PET scanning (typically, two hours) has limited the uptake of PET-hypoxia imaging as a routine screening modality. In contrast, magnetic resonance imaging (MRI) is standard for diagnosis of STS and is a routine part of the radiation therapy workflow due to its superior contrast between tumour and surrounding normal tissue. In addition, diffusion-weighted magnetic resonance imaging (DWI) can quantify physiological tumour properties such as cellularity and perfusion that may provide information about tumour biology, including hypoxia.

Hypoxia results from the interplay between oxygen demand (oxygen consumption rate) and supply (perfusion). Hypothesizing that oxygen consumption increases with increasing cellularity, Hompland and colleagues demonstrated that a biomarker derived from IVIM measurements could predict hypoxia in prostate, breast, and cervical cancer patients. An ongoing prospective imaging study of hypoxia in STS patients at Princess Margaret is investigating the capacity of FAZA to image hypoxia in STS and develop correlative DWI (IVIM)-based biomarkers of hypoxia on a combined PET/MRI scanner.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Ability to understand and the willingness to sign a written informed consent document
* Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension

Exclusion Criteria:

* Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
The Effect of Power Posing on Timed Up and Go Test Score

This study determines the effects of posture on time up and go test. Half of the subjects will assume a high-power posture, while the other half will assume a low-power posture.

Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds. Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds. Timed Up and Go test was administered using an OmniVR™ Virtual Rehabilitation System before and after the postural intervention

Eligibility Criteria:
Inclusion Criteria:

* male or female, age 18 to 65, with all 4 extremities intact, and ability to stand still for 20 seconds.

Exclusion Criteria:

* unable to stand with their feet together or one foot apart for at least 20 seconds, unable to wrap their arms around their torso or keep their hands on their hips for 20 seconds, unable to perform sit to stand transfer and ambulation independently, and cognitive impairments that interfere with the experimental procedures.